H W Nortier

Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.

P.C. de Jong, J. van de Ven, H W Nortier et al. · PubMed · 1997 · 81 citations

Medicine, Oncology, Pharmacology +16

Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.

E. van der Wall, Truus H. Donker, E. De Frankrijker et al. · PubMed · 1993 · 42 citations

Medicine, Endocrinology, Pharmacology +17

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.

Roy Lalisang, J. Wils, H W Nortier et al. · Journal of Clinical Oncology · 1997 · 30 citations

Pharmacy, Oncology, Pharmacotherapy +17

Abstract S2-3: The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study

C Seynaeve, E.T.M. Hille, Annette Hasenburg et al. · Cancer Research · 2010 · 18 citations

Pharmacy, Oncology, Pharmacotherapy +17